[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"resection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:resection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100392492","optimizing-y90-therapy-for-radiation-lobectomy-100392492",false,"NCT04390724","Optimizing Y90 Therapy for Radiation Lobectomy","Yttrium-90 Radiation Lobectomy: Dose Optimization and Prediction of FLR Hypertrophy to Enable Resection of HCC","Inclusion Criteria:\n\n1. Patients must have been diagnosed with HCC confirmed by histology or must meet one of the following American Association for the Study of Liver Diseases (AASLD) guidelines:\n\n   * AFP \\>200 and radiological evidence (arterial hypervascularity) of lesion \\> 2 cm does not require biopsy\n   * Two imaging modalities (triphasic CT, MRI, ultrasound, angiography) demonstrating arterial hypervascularity in the background of cirrhosis does not require biopsy\n   * One imaging modality with a lesion with arterial hypervascularity with wash out in early or delayed venous phase, does not require a biopsy\n2. Child-Pugh stage A\n3. Future Liver Remnant (FLR) of \\\u003C 40%\n4. ECOG Performance Status 0-1\n5. Bilirubin ≤ 3.0 mg\u002Fdl- Treatment may proceed if the Bilirubin is elevated if the tumor may be isolated from a vascular standpoint\n6. Creatinine ≤ 2.0 mg\u002Fdl\n7. ANC ≥ 1.5 K\u002FuL\n8. Platelets \\> 25 K\u002FuL\n9. Patient is willing participate in this study and has signed the consent\n10. For Group 2 patients only:\n\n    * Patients planned Y90 dose and embolic load is found to fall within the optimal dose and embolic load size from data from Group 1 patients\n\nExclusion Criteria:\n\n1. Patient must not be pregnant\n\n   NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n   * Has not undergone a hysterectomy or bilateral oophorectomy\n   * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n2. For Patients in Group 2 only:\n\n   * Patients who have contraindications to MRI:\n\n     * Patients that are claustrophobic and haven't been able to tolerate an MRI in the past. (Patients with mild claustrophobia are eligible and have the option to take\n\n       1mg oral Lorazepam prior to the MRI, if needed)\n     * Allergy to gadolinium-containing contrast media\n     * Patients with a pacemaker, metallic clip, aneurysm clips, shrapnel fragments, etc.\n     * Patients with an eGFR \\\u003C 30 mL\u002Fmin\u002Fm²\n3. Must not have any significant life-threatening extra-hepatic disease or life- threatening secondary malignancies, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be HIV positive or have acute HBV or HCV\n4. Must not have any contraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents (e.g. closure device)\n5. Must not have any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of TheraSphere treatment, in the Investigator's judgment\n6. History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically\n\n   \\-","ALL","18 Years",{"count":19,"type":20},104,"ESTIMATED","OBSERVATIONAL","HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.",[24,25,26,27,28],"HCC","Resection","Transplant","Metastatic Cancer","Adult Primary Liver Cancer",[24,30,31,32,33],"Y90 Radioembolization","Liver Resection","Liver Transplant","Liver Cancer","RECRUITING","2026-03-23",{"date":37,"type":38},"2026-03-27","ACTUAL",{"date":40,"type":38},"2020-07-17",{"date":42,"type":20},"2026-07",{"name":44,"class":45},"Northwestern University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100556665","treatment-of-anastomotic-leakage-after-colon-cancer-resection-100556665","NCT06528054","TreatmENT of AnastomotiC LeakagE After COLON Cancer Resection","TreatmENT of AnastomotiC LeakagE After COLON Cancer Resection: the TENTACLE - Colon Study","TENTACLE-Colon","Inclusion criteria:\n\n* Aged 18 years or older;\n* Surgical resection for primary colon cancer (cT1-4b, N0-2, M0-1) with formation of a primary colonic anastomosis and with or without diverting stoma;\n* Postoperative AL defined as: \"any clinical, radiological or intraoperative signs of disrupted integrity of the anastomosis. This also includes suspected leaks with any degree of extraluminal air or fluid on CT, perianastomotic abscess, purulent peritonitis without clear anastomotic defect, or any other suspicious condition in which there is no ultimate macroscopic proof of disrupted anastomosis.\"\n* Regarding the type of colon cancer resection, the following patients will also fulfil the inclusion criteria: patients who underwent cytoreductive surgery (CRS) simultaneous with resection of the primary colon cancer with or without hyperthermic intraperitoneal chemotherapy (HIPEC), simultaneous ablations\u002Fresections of metastasis, multivisceral resection, emergency resection, patients diagnosed with perforated disease\u002Fperitumoral abscess or fistula, and acute obstructions.\n\nExclusion criteria:\n\n* Surgical resection for benign colon disease;\n* Recurrent colon cancer resection;\n* Any primary colon malignancy other than adenocarcinoma (e.g. neuroendocrine tumour, gastrointestinal stromal tumour);\n* Any clinical condition that does not fulfil the broad definition of AL as used in this study (e.g. only free air on CT that is considered to be compatible with an appropriate postoperative day in the absence of any other clinical signs related to a potential anastomotic leakage)",{"count":55,"type":20},2000,"This international multicentre retrospective cohort study aims to research anastomotic leakage after colon cancer resection and has two main objectives:\n\n1. To identify predictive factors associated with 90-day mortality and 90-day Clavien-Dindo grade 4-5 complications amongst patients who developed AL following colon cancer resection and to develop and validate a prediction model for predicting 90-day mortality as well as the co-primary composite endpoint Clavien-Dindo grade 4-5 complications.\n2. To explore and compare the effectiveness of various treatment strategies for AL following colon cancer resection, considering patient, tumour, resection and leakage characteristics.",[58,59,25,60],"Treatment","Anastomotic Leakage","Colon Cancer","NOT_YET_RECRUITING","2024-07-29",{"date":64,"type":38},"2024-07-30",{"date":66,"type":20},"2024-10",{"date":68,"type":20},"2026-03",{"name":70,"class":45},"Radboud University Medical Center"]